Brief: Kiniksa Pharmaceuticals Provides Corporate And Portfolio Update
Kiniksa Pharmaceuticals Ltd KNSA.O :
* KINIKSA PHARMACEUTICALS PROVIDES CORPORATE AND PORTFOLIO
UPDATE
* KINIKSA PHARMACEUTICALS LTD - CASH RESERVES EXPECTED TO
FUND
OPERATIONS INTO AT LEAST 2025
* KINIKSA PHARMACEUTICALS LTD - DATA OF KPL-404 PHASE 2
TRIAL IN
RHEUMATOID ARTHRITIS EXPECTED IN 1H 2024
Source text for Eikon: ID:nGNX5TxFRq
Further company coverage: KNSA.O
Recent news on Kiniksa Pharmaceuticals International
See all newsKiniksa Pharmaceuticals International, PLC reports results for the quarter ended June 30 - Earnings Summary
Kiniksa Pharmaceuticals Q2 product revenue rises on ARCALYST sales
Kiniksa Pharmaceuticals International, PLC expected to post earnings of 30 cents a share - Earnings Preview
Cardiovascular drugmaker Kiniksa's Q1 net income rises
Kiniksa Q4 revenue rises on ARCALYST sales